239087-06-0

Basic information

• Product Name: 2-FLUORO-6-(TRIFLUOROMETHYL)BENZYLAMINE
• Synonyms: 2-FLUORO-6-(TRIFLUOROMETHYL)BENZYLAMINE;2-Chloro-6-(trifluoroMethyl)benzylaMine, JRD, 97%;2-(Aminomethyl)-3-fluorobenzotrifluoride, [2-Fluoro-6-(trifluoromethyl)phenyl]methylamine;(2-fluoro-6-(trifluoroMethyl)phenyl)MethanaMine;(2-fluoro-6-(trifluoroMethyl)phenyl)MethanaMine hydrochloride;elagolix intermediate 1;1-[2-Fluoro-6-(trifluoromethyl)phenyl]methanamine;OTF-BYM-6F
• CAS NO: 239087-06-0
• Molecular Formula: C₈H₇F₄N
• Molecular Weight: 193.14
• Product Categories: Amine
• Mol File: 239087-06-0.mol

Chemical Properties

• Boiling Point: 173.161 °C at 760 mmHg
• Flash Point: 69.713 °C
• Appearance: /
• Density: 1.313 g/cm³
• Refractive Index: 1.4925
• Storage Temp.: Store under Nitrogen
• PKA: 7.84±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 2-FLUORO-6-(TRIFLUOROMETHYL)BENZYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUORO-6-(TRIFLUOROMETHYL)BENZYLAMINE(239087-06-0)
• EPA Substance Registry System: 2-FLUORO-6-(TRIFLUOROMETHYL)BENZYLAMINE(239087-06-0)

Safety Data

• Hazard Codes: C
• Statements: 36/37/38
• Safety Statements: 26-36
• HazardClass: 8
• Hazardous Substances Data: 239087-06-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-FLUORO-6-(TRIFLUOROMETHYL)BENZYLAMINE is used as an intermediate in the synthesis of Elagolix and its salts for the development of pharmaceutical products. It plays a crucial role in the production process, contributing to the creation of medications that can potentially address various health conditions.

InChI:InChI=1/C9H10F3N/c1-6-3-2-4-8(7(6)5-13)9(10,11)12/h2-4H,5,13H2,1H3

Upstream product

• 133116-83-3 2-fluoro-6-(trifluoromethyl)benzonitrile 
• 581072-15-3 2-fluoro-6-(trifluoromethyl)benzaldehyde oxime 
• 401-80-9 3-fluoro-trifluoromethylbenzene 
• 60611-24-7 2-fluoro-6-(trifluoromethyl)benzaldehyde 
• 643088-07-7 2-fluoro-6-(trifluoromethyl)benzylamine hydrochloride 
• 32890-94-1 2-fluoro-6-(trifluoromethyl)benzoic acid 
• 152211-15-9 (2-fluoro-6-(trifluoromethyl)phenyl)methanol 

Downstream Products

• 830346-46-8 N-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}urea 

Relevant articles and documents

Preparation method of Elagolix intermediate 2-fluoro-6-trifluoromethyl benzylamine

The invention discloses a preparation method of an Elagolix intermediate 2-fluoro-6-trifluoromethyl benzylamine, and belongs to the technical field of medical intermediates. The preparation method comprises the following steps: (1) synthesizing 2-fluoro-6-(trifluoromethyl) benzyl alcohol; (2) synthesizing 2-fluoro-6-(trifluoromethyl) benzyl alcohol; (3) synthesizing a 2-fluoro-6-(trifluoromethyl)benzenemethanesulfonate compound and a phthalimide compound; (4) directly synthesizing a phthalimide compound; (5) synthesizing the 2-fluorine-6-trifluoromethyl benzylamine. According to the preparation method, factors such as a reaction reagent and a reaction solvent are optimized, so the reaction conditions are mild, the technological process is simple and convenient, the requirements on equipment are relatively low, the price of raw materials is lower, the purity of the obtained product is high, and industrial production is facilitated.

[...] and its sodium salt intermediate and its salt preparation method and application (by machine translation)

The invention application [...] and its sodium salt intermediate and its salt preparation method and application, relates to medical intermediate and its preparation method and application. The present invention provides a process content provided by the

PROCESSES TO PRODUCE ELAGOLIX

The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.

Method for preparing GnRHR drug key intermediate compound

The invention discloses a method for preparing a GnRHR drug key intermediate compound. According to the invention, a synthetic route of the GnRHR drug key intermediate is changed, and meanwhile, a boron hydrogen salt is taken as a reducing agent and a chl

Method for preparing intermediate of elagolix

The invention relates to a method for preparing an intermediate of elagolix. In particular, the invention discloses a method for preparing a key intermediate compound E8 of elagolix, and compounds such as a compound E4 for preparing the intermediate compound E8. The method is simple and convenient in operation, mild in condition and very applicable to industrial production.

Method for preparing agomelatine intermediate (by machine translation)

The invention relates to a method for preparing an intermediate of agomelatine. The method is simple and convenient to E8 operate, mild E8 in condition and very suitable for industrial production C. (by machine translation)

Synthesis method of key raw material compound C of Elagolix

The invention relates to a synthesis method of a key raw material compound C of Elagolix. The synthesis method comprises the following steps: performing reaction of 3-flourine-trifluorotoluene, an organic lithium reagent and DMF in the presence of TMEDA a

Discovery of sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6- [trifluoromethyl]-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl] -1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor

The discovery of novel uracil phenylethylamines bearing a butyric acid as potent human gonadotropin-releasing hormone receptor (hGnRH-R) antagonists is described. A major focus of this optimization was to improve the CYP3A4 inhibition liability of these uracils while maintaining their GnRH-R potency. R-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl) -4-methyl-2,6-dioxo-3,6-dihy-dro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyric acid sodium salt, 10b (elagolix), was identified as a potent and selective hGnRH-R antagonist. Oral administration of 10b suppressed luteinizing hormone in castrated macaques. These efforts led to the identification of 10b as a clinical compound for the treatment of endometriosis.

PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure formula (I) wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

PYRIMIDINE-2, 4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.